Skip to content

Ranked by human evidence

Best Peptides for Recovery and Healing, Ranked by Evidence

BPC-157 ranks first for recovery and healing, and its human evidence is small: 5 studies in about 80 people, with no significant benefit in the one placebo-controlled trial. I found no published human trial of TB-500, and FDA found no human study of KPV by any route.

Animal studies suggest BPC-157 and TB-500 may support tendon, muscle and gut-lining repair. In people, BPC-157 has only small studies and TB-500 has none published. Both are sold research-use-only, not approved for human use.

Related: Best peptides for joint pain · Peptides for inflammation · Peptides for gut health · Collagen peptides for joints · BPC-157 vs TB-500

Peptides for recovery and healing, ranked by human evidence

The order is the strength of human evidence, strongest first: strong, moderate, limited, animal or lab only, then none. Ties keep the site's usual compound order. A higher rank means more and better human studies, not that a compound works for recovery and healing, so check what each study measured.

Peptides for recovery and healing compared: evidence level, US legal status and what human studies measured
RankCompoundEvidenceUS statusMeasured in humansGuide
1BPC-157Limited human dataResearch use only5 small studies in about 80 people; the one placebo-controlled trial, in ulcerative colitis, showed no significant benefit.Read
2HGH 191AALimited human dataResearch use onlySomatropin's approval trials, in growth hormone deficiency and related conditions; never in healthy adults for muscle, recovery or aging.Read
3TB-500Animal / lab onlyResearch use onlyNone I could find published; much of the research cited for it studied full-length thymosin beta-4.Read
4KPVAnimal / lab onlyResearch use onlyNone: FDA found no human study by any route.Read
5PEG-MGFAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
6MGFAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
7CartalaxAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
  1. Research peptidesResearch use only

    1. BPC-157

    Limited human data

    Measured in humans: 5 small studies in about 80 people; the one placebo-controlled trial, in ulcerative colitis, showed no significant benefit.

    Why this rating

    Rodent-dominated for efficacy: no BPC-157 study is indexed in PubMed under a clinical-trial or randomized-controlled-trial publication type (queried 2026-07-15). The published human experience is five small studies totalling roughly 80 people. The only randomized placebo-controlled trial in patients - 53 people, ulcerative colitis - was never published beyond a meeting abstract, and its between-group difference spanned zero. So human evidence exists; it is tiny and null, which is not the same as absent.

  2. Research peptidesResearch use only

    2. HGH 191AA

    Limited human data

    Measured in humans: Somatropin's approval trials, in growth hormone deficiency and related conditions; never in healthy adults for muscle, recovery or aging.

    Why this rating

    The parent molecule, somatropin, has strong trial evidence for its FDA-approved indications - growth hormone deficiency, Turner and Prader-Willi syndromes, and related conditions - reflected in approved drug labels (see externalRefs). None of that trial evidence was collected in healthy adults using it for the muscle, recovery or anti-aging claims this research-sold product is marketed for, and no clinical trial of a research-channel "HGH 191AA" vial itself exists. That gap - real drug, unstudied off-label consumer use, unverified vial - keeps this record at "limited" rather than higher.

  3. Research peptidesResearch use only

    3. TB-500

    Animal / lab only

    Measured in humans: None I could find published; much of the research cited for it studied full-length thymosin beta-4.

    Why this rating

    In vitro and animal work only. I could not locate a published human randomized controlled trial of the heptapeptide for any indication. Much of the tissue-repair literature cited for TB-500 appears to have studied full-length thymosin beta-4 - a different molecule - so even the preclinical base is likely thinner than it looks. There is no human evidence here that I could find.

  4. Research peptidesResearch use only

    4. KPV

    Animal / lab only

    Measured in humans: None: FDA found no human study by any route.

    Why this rating

    Cells and animals only. FDA's July 2026 briefing document states that neither the nominator nor FDA identified any clinical study or human exposure data for KPV by any route. A PubMed search for KPV as a peptide (queried 23 September 2026) returns 110 records and zero indexed under a clinical-trial or randomised-controlled-trial publication type.

  5. Research peptidesResearch use only

    5. PEG-MGF

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    Human evidence is essentially absent. FDA states it has identified no human exposure data on PEG-MGF administered by any route. The literature on native mechano growth factor is rodent and cell-culture work - for example, MGF messenger RNA rising quickly after muscle damage in rats (Hill 2003), and a synthetic MGF E peptide improving transplanted muscle-cell engraftment in mice (Mills 2007) - not a study of the synthetic, PEGylated consumer product. The one human study usually cited (Hameed 2003) measured MGF messenger RNA switched on by exercise in people's own muscle; nobody was injected. Researchers at two pharmaceutical companies could not reproduce the claimed effects of the MGF peptide on muscle cells (Fornaro 2014). No completed human trial has tested injected PEG-MGF for any outcome.

  6. Research peptidesResearch use only

    6. MGF

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    The evidence base is animal and cell-culture research into a natural splice variant of IGF-1, not a human trial of the synthetic peptide sold as MGF. The cell findings conflict: early work reported that the MGF E peptide boosted muscle precursor cell growth (Yang 2002; Kandalla 2011), but an independent two-company attempt found no effect on myoblasts or muscle stem cells (Fornaro 2014). Animal work includes heart-attack models in sheep (Carpenter 2008). No completed human trial has tested injected MGF for muscle growth, recovery or any outcome. That places it at "preclinical" - the same tier as PEG-MGF, its longer-acting relative.

  7. Research peptidesResearch use only

    7. Cartalax

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    I could not find a single PubMed-indexed paper that studies Cartalax by that name, and a direct title/abstract search for "Cartalax" returns zero results. Two papers from the same Russian research group do dose the identical Ala-Glu-Asp sequence under the lab code "T-31", in organotypic and cultured kidney (renal) cell models from young and old rats, reporting increased cell proliferation and reduced senescence markers. That is real, citable, cell-culture evidence for this exact molecule - but it is evidence about kidney cells, not the cartilage or joint tissue the product is marketed for. The same group has also dosed it in living rats: in cisplatin-induced kidney failure (less protein and electrolytes in the urine), in old rats (more urine output, less urine protein, no signs of kidney toxicity), and, as T-31, in an ovariectomy model of osteoporosis (less bone-density loss than untreated rats, less effect than a cartilage extract). No human study of any kind is verifiable for this peptide.

Common questions about peptides for recovery and healing

Do peptides really work for recovery?

I found no peptide sold for recovery with a controlled human trial showing it speeds healing. BPC-157 has consistently positive rat studies, but its one placebo-controlled human trial showed no significant benefit. TB-500 has one positive rat tendon study, and I found no published human trial.

Is BPC-157 good for injury recovery?

In rats, the tissue-healing studies are consistently positive. In people, the only injury data is one uncontrolled chart review of 17 people with knee pain. It is not FDA-approved, and its human half-life is unknown.

Does BPC-157 work immediately?

No study I found measured how quickly it works in people. Its one placebo-controlled trial showed no significant benefit, and its human half-life is unknown, so any timeline you read online comes from personal reports, not trials.

Is BPC-157 hard on your liver?

It hasn't been established either way. In a 2-person pilot, intravenous doses caused no measurable change in liver, kidney, heart, thyroid or blood-sugar markers. FDA's review noted liver-related signals, including a raised liver enzyme (ALT), in 28-day rat and dog studies. Two people and short courses can't show liver safety.

Which is better for recovery, BPC-157 or TB-500?

I found no controlled human trial of either for injury. BPC-157 has 5 small human studies, and I found none published for TB-500. Much of the research cited for TB-500 studied full-length thymosin beta-4, a different molecule from the 7-amino-acid fragment that is sold.

What peptides has Joe Rogan said he used?

On his podcast in July 2021 (episode 1683), Joe Rogan said elbow tendonitis he could not fix was gone within two weeks of starting BPC-157. In September 2021 CBS News and Variety reported he said he had an NAD drip while he had COVID-19; NAD is a coenzyme, not a peptide. One person's account is not a trial, and the one trial testing BPC-157 against a placebo, in ulcerative colitis, showed no significant benefit.

Guides on peptides for recovery and healing

Best peptides for other goals